Biological Modification of Lymphocytes in Auto- and Allo-Immune Diseases1

  • J. W. Semple
  • J. Freedman
Conference paper
Part of the Developments in Hematology and Immunology book series (DIHI, volume 38)


he term “biologic modification” can literally be applied to any molecule or drug derived from living things which has a clinical effect. Over the last 30 years, several peptides and proteins have been developed and have shown efficacy in treating both autoimmune and alloimmune disorders. The breadth of research into protein therapeutics has become huge and it is beyond the scope of this paper to fully analyze the literature. Thus, we will briefly review some of the major protein biologies either already used in transfusion/transplantation medicine or in development and will highlight their potential mechanisms of action. It will conclude with a brief discussion on transfusion-induced immunmodulation.


Idiopathic Thrombocytopenic Purpura Immune Thrombocytopenic Purpura Whole Blood OKT3 Monoclonal Antibody Tolypocladium Inflatum 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gerber DA, Bonham CA, Thomson AW. Immunosuppressant agents: recent developments in molecular action and clinical application. Transplant Proc 1998;30:1573–79.PubMedCrossRefGoogle Scholar
  2. 2.
    Brazelton TR. Morris RE. Molecular mechanisms of action of new xenobi-otic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Current Opinion in Immunology 1996;8:710–20.PubMedCrossRefGoogle Scholar
  3. 3.
    Oppenheim JJ. Cytokines: past, present, and future. International J Hematol 2001;74:3–8.CrossRefGoogle Scholar
  4. 4.
    Tompkins WA. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. J Interferon & Cytokine Research. 1999;19:817–28.CrossRefGoogle Scholar
  5. 5.
    Randomised double-blind placebo-controlled study of interferon beta-la in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-la Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352:1498–504.CrossRefGoogle Scholar
  6. 6.
    Ohlsson K et al Interleukin 1 receptor antagonist reduces mortality from endotoxin shock Nature (London) 1990;348:550–54.CrossRefGoogle Scholar
  7. 7.
    Yoshimura, C, Nomura, S, Nagahama, M, et al: Plasma-soluble Fas (APO-1, CD95) and soluble Fas ligand in immune thrombocytopenic purpura. Eur J Haematol 2000;64:219–24.PubMedCrossRefGoogle Scholar
  8. 8.
    Erduran, E, Asian, Y, Aliyazicioglu, Y, et al: Plasma soluble interleukin-2 receptor levels in patients with idiopathic thrombocytopenic purpura. Am J Hematol 1998;57:119–23.PubMedCrossRefGoogle Scholar
  9. 9.
    Tan, B, Zhao, X, Yin, C: Detection of IL-2 receptor in patients with idiopathic thrombocytopenic purpura. Hunan Yi Ke Da Xue Xue Bao 1998;23: 191–93.PubMedGoogle Scholar
  10. 10.
    Mouzaki, A, Theodoropoulou, M, Gianakopoulos, I, et al: Expression patterns of Thl and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis. Blood 2002: in press.Google Scholar
  11. 11.
    Andersson, PO, Stockelberg, D, Jacobsson, S, et al: A transforming growth factor-beta 1- mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura. Ann Hematol 2000;79:507–13.PubMedCrossRefGoogle Scholar
  12. 12.
    Klingbeil C. Hsu DH. Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use. Toxicologic Pathology 1999;27: 1–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med. 1985;313:337–42.CrossRefGoogle Scholar
  14. 14.
    Thistlewaite JR, Cosimi AB, Delmonico FL, et al. Evolving use of OKT3 monoclonal antibody for the treatment of renal allograft rejection. Transplantation. 1984;38:695–700.CrossRefGoogle Scholar
  15. 15.
    Cosimi AB, Burton RC, Colvin RB, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation. 1981;32:535–39.PubMedCrossRefGoogle Scholar
  16. 16.
    Starzl TE, Fung JJ. Orthoclone OKT3 in treatment of allografts rejected under cyclosporine-steroid therapy. Transplant Proc. 1986;18:938–41.Google Scholar
  17. 17.
    Kuwana, M, Nomura, S, Fujimura, K, et al. Immuno-monitoring after a single injection of humanized monoclonal antibody to CD40 ligand in patients with chronic ITP. Blood 2001;98 (suppl l):441a (abstr).CrossRefGoogle Scholar
  18. 18.
    Delgado, J, Bustos, JG, Jimenez-Yuste, V, Hernandez-Navarro F, Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura. Haematologica 2002;87:215–16.PubMedGoogle Scholar
  19. 19.
    Stasi, R, Pagano, A, Stipa, E, Amadori, S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;98:952–57.PubMedCrossRefGoogle Scholar
  20. 20.
    Imbach P, Barandun S, d’Apuzzo V. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;i:1228–231.CrossRefGoogle Scholar
  21. 21.
    Blanchette VS, Semple JW, Freedman J. IVIg and anti-D in autoimmune cytopenias, In: Silberstein LE, ed. Autoimmune Disorders of Blood. Bethesda, MD: American Association of Blood Banks; 1996:35–77.Google Scholar
  22. 22.
    Phelps S J. ASHP therapeutic guidelines for intravenous immune globulin. Clin Pharm 1992;11:117–34.Google Scholar
  23. 23.
    Fehr J, Hofmann V, Kappeier U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gammaglobulin. N Engl J Med 1982;306:1254–58.PubMedCrossRefGoogle Scholar
  24. 24.
    Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001;291:484–88.PubMedCrossRefGoogle Scholar
  25. 25.
    Rossi F, Sultan Y, Kazatchkine MD. Anti-idiotypes against autoantibodies and alloantibodies to VIII :C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol 1988;74: 311–16.PubMedGoogle Scholar
  26. 26.
    Rossi F, Kazatchkine MD. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 1989;143:4104–09.PubMedGoogle Scholar
  27. 27.
    Dietrich G, Kaveri S-V, Kazatchkine MD. Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/idiotype network. Clin Immunol Immunopath 1992;62:S73–S81.CrossRefGoogle Scholar
  28. 28.
    Aukrust P, Froland SS, Liabakk NB et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994;84:2136–43.PubMedGoogle Scholar
  29. 29.
    Schiffer CA, Hogge DE, Aisner J. High dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients Blood 1984; 64:937–40.PubMedGoogle Scholar
  30. 30.
    Lee EJ, Norris D, Schiffer CA. Intravenous immune globulin for patients alloimmunized to random donor platelet transfusion. Transfusion 1987;27: 245–47.PubMedCrossRefGoogle Scholar
  31. 31.
    Knupp C, Chamberlain JK, Raab SO. High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients. Blood 1985;65: 776–81.PubMedGoogle Scholar
  32. 32.
    Slichter S J. Alloimmune refractoriness to transfused platelets. In: Garraty G, ed. Immunobiology of Transfusion Medicine. New York, NY: Marcel Dek-ker; 1994:597–627.Google Scholar
  33. 33.
    Glotz D, Haymann JP, Sansonetti N, et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg): a potential tool for transplantation of immunized patients. Transplantation 1993;56:335–41.PubMedCrossRefGoogle Scholar
  34. 34.
    Raimondi E, Casadei D, Rial M, Goldberg M, Najum Z. Kidney transplantation in a positive cross-match (CM) patient treated with intravenous gammaglobulin in high dose (IvgHD) J Am Soc Nephrol 1994;5:1031–36.Google Scholar
  35. 35.
    Raimondi E, Perrone S, Favaloro RG, Favaloro R, Haas E. Cardiac transplantation in a positive cross-match treated with intravenous gammaglobulin in high doses (IVGHD). Hum Immunol 1993;37 (suppl):106 (abstr).Google Scholar
  36. 36.
    Tyan DB, Li VA, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplant with a histocompatible organ. Transplantation 1994;57:553–59.PubMedGoogle Scholar
  37. 37.
    Urra JM, d la Torre M, Alcázar R, Peces R, Ferraras I, Garcia-Chico P. Variable in vitro inhibition of HLA-specific alloantibody-mediated cytotoxicity by intravenous human immunoglobulin. Transpl Proc 1998;30:4177–79.CrossRefGoogle Scholar
  38. 38.
    McIntyre JA, Higgins N, Britton R, et al. Utilization of IVIg to ameliorate anti-HLA antibodies in a highly sensitized patient awaiting cardiac transplant with a Novacor cardiac assist device. Hum Immunol 1996;49 (suppl): 90 (abstr).Google Scholar
  39. 39.
    Mahoney RJ, Breggia AC. Intravenous immunoglobulin Ginhibition of crossmatches by IgG F(ab’)2 dimers, monomers, Fab-fragments and monomeric whole IgG products. In: Cunningham RK, ed. Proceedings of the Fifth Basic Sci Symp of the Transplantation Soc. Chautauqua, NY: Chautauqua Inst 1997:126.Google Scholar
  40. 40.
    Casadei D, Rial M, Raimondi E, Goldberg J, Argento J, Haas E. Immunoglobulin IV high dose (IVIg HD): new therapy as a rescue treatment of grafted kidneys. Transplant Proc 1996;8:3290–91.Google Scholar
  41. 41.
    Peraldi MN, Akposso K, Haymann JP, et al. Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation. Transplantation 1996;62:1670–75.PubMedCrossRefGoogle Scholar
  42. 42.
    Mahoney RJ, Breggia AE. Inhibition of HLA antibody cytotoxicity by intravenous immunoglobulin G F(ab’)2 dimers, monomers, and monovalent F(ab). Hum Immunol 1999;60:492–98.PubMedCrossRefGoogle Scholar
  43. 43.
    Salama A, Kiefel V, Amberg R et al. Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D)]. Blut 1984;49:29–35.PubMedCrossRefGoogle Scholar
  44. 44.
    Zimmerman SA, Malinoski FJ, Ware RE. Immunologic effects of anti-D (WinRho-SD) in children with immune thrombocytopenic purpura. Am J Hematol 1998;57:131–38.PubMedCrossRefGoogle Scholar
  45. 45.
    Kumpel BM, Elson CJ. Mechanism of anti-D-mediated suppression — a paradox awaiting resolution. Trends in Immunology 2001;22:26–31.PubMedCrossRefGoogle Scholar
  46. 46.
    Semple JW, Allen D, Rutherford M, Woloski M, David M, Wakefield C, Butchart S, Freedman J, Blanchette V. Canadian Children’s Platelet Study Group. Anti-D (WinRho SD) treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production. Am J Hematol 2002;69:225–27.PubMedCrossRefGoogle Scholar
  47. 47.
    Ruiz de Souza V. Carreno MP. Kaveri SV. Et al. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal poly specific IgG (intravenous immunoglobulin). Eur J Immunology 1995;25:1267–73.CrossRefGoogle Scholar
  48. 48.
    Chess, L. Blockade of the CD40L/CD40 pathway, in Austen KF, Burakoff, S, Rosen, F & Strom, T (eds): Therapeutic Immunology, 2nd edn. New York, Blackwell Sciences, 2001, pp 441–56.Google Scholar
  49. 49.
    Coutinho, A, Haas, W. In vivo models of dominant T-cell tolerance: where do we stand today? Trends Immunol 2001;22:350–51.PubMedCrossRefGoogle Scholar
  50. 50.
    Mackay, IR. The “autoimmune diseases” 40th anniversary. Autoimmunity Rev 2002;1:5–11.CrossRefGoogle Scholar
  51. 51.
    Opelz G, Sengar DPS, Mickey MR et al. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 1973;5:253–59.PubMedGoogle Scholar
  52. 52.
    Lenhard V, Mytilineos J, Hansen B et al. Immunoregulation after blood transfusions in the rat model ~ anti-idiotypic antibodies or suppressor cells? Transplant Proc 1985;17:2393–96.Google Scholar
  53. 53.
    Ludwin D, Stary S, Singal DP. Suppressor cell generation in mice after blood transfusions from different H-2 donors. Transplant Proc 1987;21: 3402–05.Google Scholar
  54. 54.
    Wood ML, Gottschalk R, Monaco AP. Immune reactivity of congenic mice after allogeneic or isogeneic transfusion. Transplantation 1986;41:489–97.PubMedCrossRefGoogle Scholar
  55. 55.
    Bektas H, Jorns Klempnauer J: Differential effect of donor-specific blood transfusion after kidney, heart, pancreas and skin transplantation in major histocompatibility complex-incompatible rats. Transfusion 1997;37:226–30.PubMedCrossRefGoogle Scholar
  56. 56.
    Quigley RL, Wood KJ, Morris PJ. Transfusion induces blood donor-specific suppressor cells. J Immunol 1989;142:463–70.PubMedGoogle Scholar
  57. 57.
    Blajchman MA, Bardossy L, Carmen RE at al. An animal model of allogenic donor platelet refractoriness: The effect of the time of leukodepletion. Blood 1992;79:1371–75.Google Scholar
  58. 58.
    Bordin JO, Bardossy L, Blajchman MA. Experimental animal model of refractoriness to donor platelets: the effect of plasma removal and the extent of white cell reduction on allogeneic alloimmunization. Transfusion 1993;33:798–801.PubMedCrossRefGoogle Scholar
  59. 59.
    Donnelly PK, Proud G, Shenton BK et al. Transfusion-induced immunosuppression and red cells clearance. Transfusion Med 1991;1:217–21.CrossRefGoogle Scholar
  60. 60.
    Fabre JW, Bishop M, Sen T et al. A study of three protocols of blood transfusion before renal transplantation in the dog. Transplantation 1978; 26:94–98.PubMedCrossRefGoogle Scholar
  61. 61.
    Quigley RL, Wood KJ, Morris PJ. Investigation of the mechanism of active enhancement of renal allograft survival by blood transfusion. Immunol 1988;163:373–81.Google Scholar
  62. 62.
    Soulillou J-P, Bignon JD, Peyrat MA. Genetics of the blood transfusion effect on heart allografts in rats. Transplantation. 1994;38:63–67.CrossRefGoogle Scholar
  63. 63.
    Shirwan H, Wang HK, Barwari L et al. Pretransplant injection of allograft recipients with donor blood or lymphocytes permits allograft tolerance without the presence of persistent donor chimerism. Transplantation 1996;61: 1382–86.PubMedCrossRefGoogle Scholar
  64. 64.
    Wood PJ, Roberts ISD, Yang C-p et al. Prevention of chronic rejection by donor-specific blood transfusion in a new model of chronic cardiac allograft rejection. Transplantation 1996;61:1440–43.PubMedCrossRefGoogle Scholar
  65. 65.
    Waymack JP, Ferneandez G, Yurt RW et al. Effect of blood transfusions on immune function. Part VI. Effect on immunologic response to tumour. Surgery 1990;108: 172–78.PubMedGoogle Scholar
  66. 66.
    Bordin JO, Bardossy L, Blajchman MA. Growth enhancement of established tumors by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion: The importance of the timing of the leukodepletion. Blood 1994;84: 344–48.PubMedGoogle Scholar
  67. 67.
    Rustoven JJ. Blood transfusion and cancer: clinical studies. In: Singal DP ed. Immunological effects of blood transfusion. Boca Raton FL: CRC press, 1995:85–110.Google Scholar
  68. 68.
    Tartter PI. Blood transfusion and bacterial infections: clinical studies. In: Singal DP ed. Immunological effects of blood transfusion. Boca Raton FL: CRC press, 1995:111–26.Google Scholar
  69. 69.
    Jensen LS, Anderson AJ, Christiansen PM et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Brit J Surgery 1992;79:513–16.CrossRefGoogle Scholar
  70. 70.
    Vamvakas EC, Moore SB. Blood transfusion and postoperative septic complications. Transfusion 1994;34:714–27.PubMedCrossRefGoogle Scholar
  71. 71.
    Dallman MJ, Wood KJ, Morris PJ. Recombinant interleukin-2 (IL-2) can reverse the blood transfusion effect. Transplant Proc 1989;21:1165–67.PubMedGoogle Scholar
  72. 72.
    Babcock GF, Alexander JW: The effects of blood transfusion on cytokine production by Th1 and Th2 lymphocytes in the mouse. Transplantation 1996;61:465–70.PubMedCrossRefGoogle Scholar
  73. 73.
    Kalechman Y, Gafter U, Sobelman D, Sredni B. The effect of a single whole-blood transfusion on cytokine secretion. J Clin Immunol 1990; 10:99–105.PubMedCrossRefGoogle Scholar
  74. 74.
    Mosmann TR, Coffman RL. Thl and Th2 cells: different patterns of lympho-kine secretion lead to different functional properties. Ann Rev Immunol 1989;7:145–73.CrossRefGoogle Scholar
  75. 75.
    Romagnani S. Thl and Th2 in human diseases. Clin Exp Immunol. 1996;80: 225–35.Google Scholar
  76. 76.
    Snapper CM, Paul WE. Interferon-g and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1986;236:944–47.CrossRefGoogle Scholar
  77. 77.
    Cher D, Mosman TR. Two types of mouse helper T cell clones: II. Delayed-type hypersensitivity is mediated by Thl clones. J Immunol 1987;138:3688–95PubMedGoogle Scholar
  78. 78.
    O’Connell P, Pacheco-Silva A, Nickerson P. Unmodified pancreatic islet allograft rejection results in the preferential expression of certain T cell activation transcripts. J Immunol 1993;150:1093–104.PubMedGoogle Scholar
  79. 79.
    Thai NL Fu F, Qian S et al. Cytokine mRNA profiles in mouse orthotopic liver transplantation. Graft rejection is associated with augmented Thl function. Transplantation 1995;59:274–81.PubMedGoogle Scholar
  80. 80.
    Egawa H, Martinez OM, Quinn MB et al. Acute liver allograft rejection in the rat. An analysis of the immune response. Transplantation 1995;59:97–104.PubMedCrossRefGoogle Scholar
  81. 81.
    Takeuchi T, Lowry RP, Konieczny B. Heart allografts in mouse systems: the differential activation of Th2-like effector cells in peripheral tolerance. Transplantation 1992;53:1281–89.PubMedCrossRefGoogle Scholar
  82. 82.
    Hayashi M, Martinez OM, Garcia-Kennedy R et al. Expression of cytokines and immune mediators during chronic liver allograft rejection. Transplantation 1995;60:1533–41.PubMedCrossRefGoogle Scholar
  83. 83.
    Landorfo S, Cofano F, Giovarelli P et al. Inhibition of interferon-gamma may suppress allograft reactivity by T lymphocytes in vitro and in vivo. Science 1985;229:176–79.CrossRefGoogle Scholar
  84. 84.
    Chen N, Field EH. Enhanced type 2 and diminished type 1 cytokines in neonatal tolerance. Transplantation 1995;59:933–41.PubMedCrossRefGoogle Scholar
  85. 85.
    Mottra, PL, Han W-R, Purcell LJ et al. Increased expression of IL-4 and ILIO and decreased expression of IL-2 and interferon-γ in long-surviving mouse heart allografts after brief CD4-monoclonal antibody therapy. Transplantation 1995;59:559–65.Google Scholar
  86. 86.
    Donckier V, Wissing M, Bruyns C et al. Critical role of interleukin 4 in the induction of neonatal transplantation tolerance. Transplantation 1995;59: 1571–76.PubMedGoogle Scholar
  87. 87.
    Piccotti JR, Chan SY, VanBuskirk AM et al. Are Th2 helper T lymphocytes beneficial, deleterious, or irrelevant in promoting allograft survival. Transplantation 1997;63:619–24.PubMedCrossRefGoogle Scholar
  88. 88.
    Martinez OM, Vilanueva JC, Lake J et al. IL-2 and IL-5 gene expression in response to alloantigen in liver allograft recipients and in vitro. Transplantation 1993;55:1159–67.PubMedCrossRefGoogle Scholar
  89. 89.
    Chan SY, DeBruyne LA, Goodman RE et al. In vivo depletion of CD8+ T cells results in Th2 cytokine production and alternative mechanisms of allograft rejection. Transplantation 1995;59:1155–61.PubMedGoogle Scholar
  90. 90.
    Semple JW, Freedman J: The basic immunology of platelet-induced alloimmunization. In: Current issues in platelet transfusion therapy and platelet alloimmunity. (TS Kickler, JH Herman eds). American Association of Blood Banks, Bethesda MD. 1999;77–101.Google Scholar
  91. 91.
    Semple JW, Freedman J: Leukoreduction just dosen’t “take away” immunogenic leukocytes, it creates an immuosuppressive leukocyte dose. Vox Sanguinis 2002;83 (Supp l):425–27.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2003

Authors and Affiliations

  • J. W. Semple
  • J. Freedman
    • 1
  1. 1.Dept Lab Medicine and Pathobiology, St. Michael’s Hospital, Depts Pharm, Med and Lab Medicine and Pathobiology, The Canadian Blood Services and the Toronto Platelet Immunobiology GroupTorontoUniversity of TorontoTorontoCanada

Personalised recommendations